SOLARA705.85

Solara Active Pharma Sciences Limited

· Pharma & Health
₹ CrorePeersINDSWFTLABDCALSMSPHARMAHIKALPANACEABIOSAIPARENTINDOCOUNICHEMLABMcap ₹3,142 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation103.399.399.7
+ Finance Costs105.1114.894.8
+ Interest Income-2.2-0.8-1.4
+ Share-based Payments0.62.74.7
+ Unrealised FX (Gain) / Loss-0.5-1.50.2
+ Other Non-cash Items200.7-3.33.7
+ Other — Cash Effects are Investing / Financing-1.3-1.0-1.1
Changes in Working Capital
+ Inventories13.141.80.0
+ Trade Receivables — Current178.219.8-111.3
+ Other Current Assets-20.8-10.032.0
+ Trade Payables — Current7.3-59.425.9
+ Other Current Liabilities12.910.915.2
Cash from Operating Activities
Profit Before Tax (per I/S)-488.40.5-7.4-1.6
+ Total Adjustments (incl. Working Capital)596.4213.2162.4
Cash from Operations (pre-tax)108.0213.7155.0
+ Income Taxes Paid-0.90.92.1
Cash from Operating Activities108.9212.8152.9
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)41.139.952.8
+ Disp of Fixed Assets1.00.00.5
+ Disp of Investment Property0.00.40.0
+ Acq of Other Long-term Assets0.00.03.0
+ Sale of Investments (Equity / Debt)0.00.00.1
+ Disp of Subsidiaries / Businesses (net)0.01.00.0
+ Loans & Advances Repaid32.40.00.0
+ Interest Received — Investing3.20.81.0
+ Other Inflows / (Outflows) — Investing1.01.0-44.6
Cash from Investing Activities-3.5-36.8-98.8
Cash from Financing Activities
+ Proceeds from Issue of Shares0.0159.0158.5
+ Proceeds from Borrowings116.475.049.5
+ Repayment of Borrowings118.5296.4165.7
+ Payment of Lease Liabilities0.02.13.6
+ Payment of Finance Lease Liabilities0.9
+ Interest Paid102.6113.192.2
+ Other Inflows / (Outflows) — Financing0.0-2.90.0
Cash from Financing Activities-105.7-180.5-53.6
Net Changes in Cash (pre-FX)-0.3-4.50.5
Net Changes in Cash-0.3-4.50.5
Closing Cash8.4
Reference Items
EBITDA-95.2206.3186.8191.7
EBITDA Margin %-7.3816.0713.6413.39
Free Cash Flow (CFO − Capex)67.8172.9100.1100.1
Free Cash Flow to Equity-164.1-103.7
Free Cash Flow per Basic Share15.2338.8422.4922.49
Price to Free Cash Flow31.39
Cash Flow to Net Income-0.19394.11-20.64
Cash Paid for Taxes-0.90.92.1
Cash Paid for Interest102.6113.192.2
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.